INTREXON CORPORATION (NYSE:XON) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On April25, 2017, the Board of Directors (the Board) of Intrexon
Corporation (the Company), upon recommendation of its Nominating
and Governance Committee, appointed Vinita D. Gupta as a
non-employee director of the Company effective April25, 2017. The
Board has not named Ms.Gupta to serve on any committees of the
Board at this time. As a non-employee director of the Company,
Ms.Gupta will be eligible to participate in the Companys
compensation arrangements for non-employee directors, as
described in the Companys annual proxy statement. Specifically,
in connection with her appointment, she was awarded 15,000 fully
vested stock options with an exercise price of $21.13, 40,000
stock options with an exercise price of $21.13, which vest 25%
each year on the anniversary of Ms.Guptas appointment, and 2,839
shares of common stock in lieu of the cash payment of her annual
retainer.
Attached as Exhibit 99.1 is a copy of a press release of Intrexon
Corporation, dated April27, 2017, describing the above matters.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.1 | Press release dated April27, 2017. |
About INTREXON CORPORATION (NYSE:XON)
Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. Its technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform. INTREXON CORPORATION (NYSE:XON) Recent Trading Information
INTREXON CORPORATION (NYSE:XON) closed its last trading session up +0.14 at 21.47 with 878,904 shares trading hands.